Abstract
Present: The current funding information is incomplete. Correct: The complete funding information is given below.
| Original language | English |
|---|---|
| Number of pages | 1 |
| Journal | Oncotarget |
| Volume | 8 |
| Issue number | 33 |
| DOIs |
|
| Publication status | Published - 2017 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
Cite this
}
Correction : A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056. / Kim, Hye Ryun; Jang, Joung Soon; Sun, Jong Mu; Ahn, Myung Ju; Kim, Dong Wan; Jung, Inkyung; Lee, Ki Hyeong; Kim, Joo Hang; Lee, Dae Ho; Kim, Sang We; Cho, Byoung Chul.
In: Oncotarget, Vol. 8, No. 33, 01.01.2017.Research output: Contribution to journal › Comment/debate
TY - JOUR
T1 - Correction
T2 - A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056
AU - Kim, Hye Ryun
AU - Jang, Joung Soon
AU - Sun, Jong Mu
AU - Ahn, Myung Ju
AU - Kim, Dong Wan
AU - Jung, Inkyung
AU - Lee, Ki Hyeong
AU - Kim, Joo Hang
AU - Lee, Dae Ho
AU - Kim, Sang We
AU - Cho, Byoung Chul
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Present: The current funding information is incomplete. Correct: The complete funding information is given below.
AB - Present: The current funding information is incomplete. Correct: The complete funding information is given below.
UR - http://www.scopus.com/inward/record.url?scp=85029092649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029092649&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.20268
DO - 10.18632/oncotarget.20268
M3 - Comment/debate
AN - SCOPUS:85029092649
VL - 8
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 33
ER -